Furthermore, the NSO administration lowered the insulin receptor inhibitory effect of IOMe-AG538 by modifying the insulin-signaling pathway and by reducing the levels of advanced glycation end products (AGEs) which are proteins or lipids involved in aging and in the pathogenesis of degenerative diseases, including AD. The gene discussed is INS; the disease is Alzheimer disease.